The preclinical stages of T1D generally occur over a period of years and are characterized by the presence of islet autoantibodies in peripheral blood that target insulin and pancreatic β cell proteins, the subsequent development of impaired glucose tolerance, and then clinical T1D onset marked by hyperglycemia and the need for lifelong insulin treatment (7). The gene discussed is INS; the disease is Hyperglycemia.